A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma
Phase of Trial: Phase II
Latest Information Update: 19 May 2017
At a glance
- Drugs Brentuximab vedotin (Primary) ; Bendamustine; Rituximab
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Therapeutic Use
- Sponsors Seattle Genetics
- 19 May 2017 This trial has been completed in Spain as per European Clinical Trials Database record.
- 19 Oct 2015 Status changed from planning to recruiting, according to a Seattle Genetics media release.
- 28 Jan 2015 New trial record